-
Everolimus (RAD001): From Signal to Response
2026-09-15
A translational framework for using Everolimus (RAD001) to connect mTOR target engagement with interpretable cancer phenotypes, realistic exposure design, and stronger preclinical decisions.
-
MK-5108 (VX-689) Aurora A Workflows
2026-09-15
Build selective Aurora A experiments across biochemical, cell-cycle, retinoblastoma, and xenograft models with MK-5108 (VX-689). This guide emphasizes assay design, dose interpretation, solubility control, and the distinction between AURKA expression and demonstrated tumor dependence.
-
Butylated Hydroxyanisole (BHA) Workflow Guide
2026-09-14
Build more interpretable oxidative stress experiments with Butylated hydroxyanisole (BHA) by separating stock preparation, redox perturbation, and endpoint analysis. The workflow combines ROS detection, viability controls, and orthogonal validation so antioxidant protection is not mistaken for nonspecific assay interference.
-
Sodium chloride B7288: Buffer Preparation and QC
2026-09-14
Sodium chloride B7288 is an inorganic salt used to adjust ionic strength and osmotic balance in aqueous buffers, biochemical assays, and cell culture media workflows. This guide covers calculation, dissolution, QC, storage, and boundaries such as its incompatibility with DMSO or ethanol as preparation solvents and its lack of sterility or pH-buffer qualification.
-
Pyridostigmine, α7 Signaling, and Placental Necroptosis
2026-09-13
The reference study identifies placental necroptosis as a modifiable feature of placental ischemia-driven preeclampsia-like pathology in rats. Pharmacological evidence using pyridostigmine, α-bungarotoxin, and necrostatin-1 connects enhanced non-neuronal cholinergic signaling with reduced necroptosis, inflammation, oxidative stress, and trophoblast dysfunction.
-
Anti-inflammatory Anti-angiogenic Airway Stent
2026-09-12
Zhao and colleagues developed an electrospun airway stent, PAGL, that combines anlotinib hydrochloride with silver nanoparticles to address the linked processes of infection, inflammation, angiogenesis, and fibroblast activation in tracheal in-stent restenosis. In vitro, in vivo, and RNA-sequencing results indicate that this multifunctional design can reduce biological drivers of restenosis, although validation in longer-term and clinical models remains necessary.
-
HyperScribe All in One mRNA Synthesis Kit Plus 1
2026-09-12
The HyperScribe All in One mRNA Synthesis Kit Plus 1 combines co-transcriptional ARCA capping, 5mCTP and ψUTP incorporation, DNase treatment, and enzymatic poly(A) tailing in one workflow. It is especially useful for RNA vaccine development, modified-mRNA translation studies, and immune-response optimization where RNA quality and translational performance must be controlled together.
-
c-Myc tag Peptide: Assay Control & Mechanistic Insight
2026-09-11
The c-Myc Peptide is more than a competitive reagent: it provides a defined way to test epitope-dependent detection, distinguish abundance from activity, and improve immunoassay interpretation. This article connects c-Myc tag workflows with transcription-factor stability research while clearly separating validated applications from cross-domain hypotheses.
-
HNF4A-AS1, Ferroptosis, and Sorafenib Resistance
2026-09-11
A 2024 Theranostics study identifies liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib sensitivity in hepatocellular carcinoma by connecting METTL3-dependent m6A modification of DECR1 mRNA with PUFA availability and ferroptosis. The findings provide a mechanistic framework for studying lipid-metabolism-driven drug resistance and suggest how orthogonal metabolic assays could complement lipidomic and cell-death measurements.
-
Bifendate (DDB): An Assay-First Liver Guide
2026-09-10
Bifendate (DDB) is a versatile liver research compound with hepatoprotective, lipid-regulating, and autophagy-related activities. This assay-first guide explains how to use its mechanistic profile without confusing DDB evidence with findings from praeruptorin A studies in hepatocellular carcinoma.
-
NIH/3T3 Cells: Culture, QC, and Use
2026-09-10
NIH/3T3 Cells provide an adherent mouse fibroblast model for controlled cell expansion, cell transfection studies, viral proliferation research, and oncogene research. This guide translates the product dossier into a practical recovery, culture, assay-preparation, and QC workflow while clarifying that the product information does not establish quantitative assay performance, viral permissiveness, or clinical applicability.
-
Bifendate Inhibits Autophagy and Lipid Accumulation
2026-09-09
The reference study identifies Bifendate (DDB) as a multi-step autophagy inhibitor rather than merely a general hepatoprotective compound. Using cell-based lysosomal and lipid-accumulation models, the authors show that DDB disrupts autophagosome–lysosome fusion, lysosome acidification, and autophagic lysosome reformation while reducing oleic acid-induced lipid droplets.
-
Bifendate (DDB): Designing Better Liver Studies
2026-09-09
Bifendate (DDB) is a hepatoprotection agent with reported effects on lipid metabolism, autophagy, and drug transport. This evidence-driven guide shows how to distinguish compound-specific findings from transferable assay principles and design more interpretable liver research.
-
N1-Methylpseudo-UTP in Translational RNA Design
2026-09-08
N1-Methyl-Pseudouridine-5'-Triphosphate can convert RNA chemistry into a controllable experimental variable. This article connects in vitro transcription, RNA stability enhancement, and inhaled RNA immunotherapy while clarifying how to design assays that separate nucleotide effects from delivery biology.
-
gamma-Glu-Cys (γ-Glu-Cys) Workflow Guide
2026-09-08
gamma-Glu-Cys (γ-Glu-Cys) provides a defined intermediate for glutathione synthetase enzyme assays, glutathione metabolism research, and selected thiol-reactive peptide workflows. This guide covers preparation, storage, QC, and experimental boundaries; the material is for scientific research only and should not be used for diagnostic, therapeutic, or medical applications.